Skip to main content
. 2014 Mar 3;3(3):643–651. doi: 10.1002/cam4.218

Figure 3.

Figure 3

Recurrence-free survival rates of patients stratified based on the treatment response of tumor markers after hepatectomy. A: Tumor marker was normal before and after hepatectomy. B: Tumor marker was elevated before hepatectomy but normalized after hepatectomy. C: Tumor marker was elevated before and after hepatectomy. D: Tumor marker was normal before hepatectomy but elevated after hepatectomy. (A) Survival rates based on the treatment response of AFP. The survival rate of patients in group C was significantly lower than that of patients in group A (P = 0.0016) and in group B (P = 0.0345). (B) Survival rates based on the treatment response of DCP. The survival rate of patients in group C was significantly lower than that of patients in group A (P < 0.0001) and in group B (P = 0.0003). (C) Survival rates based on the treatment response of conventional AFP-L3. The survival rate of patients in group C was significantly lower than that of patients in groups A and B (both, P < 0.0001). (D) Survival rates based on the treatment response of highly sensitive AFP-L3. The survival rate of patients in group C was significantly lower than that of patients in group A (P = 0.0005) and patients in group B (P = 0.0065). The survival rate of patients in group D was significantly lower than that of patients in group A (P = 0.0024) and patients in group B (P = 0.0345).